Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality - Trial NCT06370000
Access comprehensive clinical trial information for NCT06370000 through Pure Global AI's free database. This Phase 4 trial is sponsored by Virginia Commonwealth University and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Virginia Commonwealth University
Timeline & Enrollment
Phase 4
Jun 01, 2024
Oct 31, 2028
Primary Outcome
Rate of completion of at least 4 cycles an oral maintenance strategy for transplant eligible AML patients in CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Summary
Test feasibility of an oral maintenance strategy for transplant eligible AML patients in
 first CR who are medically underserved or have a disadvantage in the CDC SDOH domains
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06370000
Non-Device Trial